Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Benitec Biopharma Inc.NASDAQ: BNTC
Retained Earnings · Q3 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q3 FY2026 retained earnings was -$260.91M, compared with -$212.03M a year earlier.
Context
- Retained earnings amounted to 139.5% of total assets at the end of Q3 FY2026, down 62.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -23.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (228.18M) USD
- Year-over-year change
- -19.9%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (228.18M) | -19.9% |
| FY2024 | 2024-06-30 | (190.26M) | -13.3% |
| FY2023 | 2023-06-30 | (167.89M) | -13.2% |
| FY2022 | 2022-06-30 | (148.33M) | -14.0% |
| FY2021 | 2021-06-30 | (130.12M) | — |
Retained Earnings vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 retained earnings of -$260.91M is the 2nd highest of the 10 companies compared; the peer median is -$471.81M.
- Its year-over-year change of -23.1% is the 7th highest of 10, against a peer median of -16.9%.
- Retained earnings amounts to 139.5% of total assets for BNTC, versus a peer median of 337.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $61.28M | +88.6% | -25.7% | 11.5% | |
| Mar 2026 | -$260.91M | -23.1% | — | 139.5% | |
| Mar 2026 | -$383.58M | -34.6% | — | 145.8% | |
| Mar 2026 | -$427.24M | -20.2% | — | 750.8% | |
| Mar 2026 | -$437.61M | -6.4% | — | 2776.9% | |
| Mar 2026 | -$471.81M | -15.8% | — | 430.7% | |
| Mar 2026 | -$719.65M | -16.9% | — | 337.3% | |
| Mar 2026 | -$1.01B | -23.3% | — | 239.9% | |
| Mar 2026 | -$1.22B | +1.5% | — | 447.8% | |
| Mar 2026 | -$1.46B | -24.7% | — | 276.7% | |
| Peer median (excluding BNTC) | -$471.81M | -16.9% | -25.7% | 337.3% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.